{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:01:41Z","timestamp":1790312501253,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"U.S. Department of Defense Breast Cancer Research Program","award":["HT9425-23-1-0653"],"award-info":[{"award-number":["HT9425-23-1-0653"]}],"id":[{"id":"https:\/\/ror.org\/0447fe631","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. Department of Defense Breast Cancer Research Program","award":["HT9425-23-1-0654"],"award-info":[{"award-number":["HT9425-23-1-0654"]}],"id":[{"id":"https:\/\/ror.org\/0447fe631","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA086862"],"award-info":[{"award-number":["P30CA086862"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"Patient-Centered Outcomes Research Institute","doi-asserted-by":"publisher","award":["RI-MISSOURI-01-PS1"],"award-info":[{"award-number":["RI-MISSOURI-01-PS1"]}],"id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Triple\u2011negative breast cancer (TNBC) is an aggressive disease with poor survival outcomes. With the integration of immunotherapy, the optimal neoadjuvant chemotherapy backbone remains poorly defined. We examined real-world treatment patterns and response rates among patients receiving a carboplatin-based regimen, with or without anthracyclines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective cohort study, women diagnosed 2012\u20132024 with stage I-III TNBC who received neoadjuvant carboplatin plus taxane (CbT) or CbT with anthracyclines (AC-CbT) were identified from electronic health records data from 10 sites within the Greater Plains Collaborative network. Registry-recorded physician assessment of pathologic complete response (pCR) was the primary outcome. Multivariable logistic regression evaluated whether adding anthracyclines to carboplatin-based treatment was associated with pCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 878 patients with TNBC, 41.2% received CbT and 58.8% received AC-CbT. Overall, 46% received pembrolizumab, 11.7% in the CbT group and 66.3% in the AC-CbT group. On univariate analysis, pCR rates did not differ between the CbT and AC-CbT groups (47.2% vs. 51.9%, OR\u2009=\u20091.21, 95%CI 0.92\u20131.58), among patients who underwent surgery. In multivariate adjusted analyses, AC-CbT was not associated with higher odds of pCR (aOR\u2009=\u20091.05, 95%CI 0.69\u20131.59), among patients who underwent surgery. Other patient characteristics associated with pCR included pembrolizumab use, higher-grade disease, lower stage, and age at diagnosis (40\u201349 versus 60+). Use of carboplatin-containing regimens increased substantially over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world cohort, addition of anthracycline to carboplatin-containing regimen was not associated with an improvement in pCR rates. These findings suggest clinical equipoise regarding anthracycline omission in early-stage TNBC, to be validated in prospective trials. Additional work evaluating adherence, toxicity, and long-term outcomes is needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-026-08071-8","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:37:32Z","timestamp":1788935852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes"],"prefix":"10.1007","volume":"219","author":[{"given":"Matthew R.","family":"Kroll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary C.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan M.","family":"Neuner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brahmendra R.","family":"Viyyuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Ravindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"McDougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cole G.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M. G.","family":"Fleege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Chrischilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Phadke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"8071_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, Jemal A, Siegel RL (2024) Breast cancer statistics 2024. CA Cancer J Clin 74:477\u2013495. https:\/\/doi.org\/10.3322\/caac.21863","journal-title":"CA Cancer J Clin"},{"key":"8071_CR2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP (2019) Breast Cancer Treatment: A Review. JAMA 321:288\u2013300. https:\/\/doi.org\/10.1001\/jama.2018.19323","journal-title":"JAMA"},{"key":"8071_CR3","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP (2023) Advances in systemic therapies for triple negative breast cancer. BMJ 381:e071674. https:\/\/doi.org\/10.1136\/bmj-2022-071674","journal-title":"BMJ"},{"key":"8071_CR4","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.Ccr-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ, Parmigiani G, Trippa L, Bardia A (2020) Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res 26:2838\u20132848. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-3492","journal-title":"Clin Cancer Res"},{"key":"8071_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/s1470-2045(12)70525-9","volume":"14","author":"JR Mackey","year":"2013","unstructured":"Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodr\u00edguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Hou\u00e9 V, Vogel C (2013) Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 14:72\u201380. https:\/\/doi.org\/10.1016\/s1470-2045(12)70525-9","journal-title":"Lancet Oncol"},{"key":"8071_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10549-016-4051-1","volume":"161","author":"RA Freedman","year":"2017","unstructured":"Freedman RA, Seisler DK, Foster JC, Sloan JA, Lafky JM, Kimmick GG, Hurria A, Cohen HJ, Winer EP, Hudis CA, Partridge AH, Carey LA, Jatoi A, Klepin HD, Citron M, Berry DA, Shulman LN, Buzdar AU, Suman VJ, Muss HB (2017) Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511). Breast Cancer Res Treat 161:363\u2013373. https:\/\/doi.org\/10.1007\/s10549-016-4051-1","journal-title":"Breast Cancer Res Treat"},{"key":"8071_CR7","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1093\/jnci\/djae107","volume":"116","author":"JB Vo","year":"2024","unstructured":"Vo JB, Ramin C, Veiga LHS, Brandt C, Curtis RE, Bodelon C, Barac A, Roger VL, Feigelson HS, Buist DSM, Bowles EJA, Gierach GL, de Berrington A (2024) Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors. J Natl Cancer Inst 116:1384\u20131394. https:\/\/doi.org\/10.1093\/jnci\/djae107","journal-title":"J Natl Cancer Inst"},{"key":"8071_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","volume":"6","author":"M Camilli","year":"2024","unstructured":"Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM (2024) Anthracycline Cardiotoxicity in Adult Cancer Patients: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 6:655\u2013677. https:\/\/doi.org\/10.1016\/j.jaccao.2024.07.016","journal-title":"JACC CardioOncol"},{"key":"8071_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.canrad.2016.07.101","volume":"21","author":"L Bazire","year":"2017","unstructured":"Bazire L, De Rycke Y, Asselain B, Fourquet A, Kirova YM (2017) Risks of second malignancies after breast cancer treatment: Long-term results. Cancer Radiother 21:10\u201315. https:\/\/doi.org\/10.1016\/j.canrad.2016.07.101","journal-title":"Cancer Radiother"},{"key":"8071_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10549-012-2121-6","volume":"135","author":"F Petrelli","year":"2012","unstructured":"Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S (2012) Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis. Breast Cancer Res Treat 135:335\u2013346. https:\/\/doi.org\/10.1007\/s10549-012-2121-6","journal-title":"Breast Cancer Res Treat"},{"key":"8071_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/1471-2407-10-337","volume":"10","author":"LA Smith","year":"2010","unstructured":"Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10:337. https:\/\/doi.org\/10.1186\/1471-2407-10-337","journal-title":"BMC Cancer"},{"key":"8071_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/s1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl S, O\u2019Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE Jr (2018) Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 19:497\u2013509. https:\/\/doi.org\/10.1016\/s1470-2045(18)30111-6","journal-title":"Lancet Oncol"},{"key":"8071_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/jco.2014.57.0572","volume":"33","author":"WM Sikov","year":"2015","unstructured":"Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP (2015) Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 33:13\u201321. https:\/\/doi.org\/10.1200\/jco.2014.57.0572","journal-title":"J Clin Oncol"},{"key":"8071_CR14","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/s1470-2045(14)70160-3","volume":"15","author":"G von Minckwitz","year":"2014","unstructured":"von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, K\u00fcmmel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M (2014) Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 15:747\u2013756. https:\/\/doi.org\/10.1016\/s1470-2045(14)70160-3","journal-title":"Lancet Oncol"},{"key":"8071_CR15","doi-asserted-by":"publisher","unstructured":"Taglialatela I, Ruffilli B, Conte B, D\u2019Avanzo F, Rossi V, Nardin S, Gennari A (2025) Updating the Role of Carboplatin Added to Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis. Cancers (Basel) 17. https:\/\/doi.org\/10.3390\/cancers17243961","DOI":"10.3390\/cancers17243961"},{"key":"8071_CR16","doi-asserted-by":"publisher","first-page":"103712","DOI":"10.1016\/j.breast.2024.103712","volume":"75","author":"SR Mason","year":"2024","unstructured":"Mason SR, Willson ML, Egger SJ, Beith J, Dear RF, Goodwin A (2024) Platinum chemotherapy for early triple-negative breast cancer. Breast 75:103712. https:\/\/doi.org\/10.1016\/j.breast.2024.103712","journal-title":"Breast"},{"key":"8071_CR17","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O\u2019Shaughnessy J (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 382:810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"key":"8071_CR18","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Im SA, Untch M, Fasching PA, Mouret-Reynier MA, Foukakis T, Ferreira M, Cardoso F, Zhou X, Karantza V, Tryfonidis K, Aktan G, O\u2019Shaughnessy J (2024) Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med 391:1981\u20131991. https:\/\/doi.org\/10.1056\/NEJMoa2409932","journal-title":"N Engl J Med"},{"key":"8071_CR19","doi-asserted-by":"publisher","first-page":"100061","DOI":"10.1016\/j.esmorw.2024.100061","volume":"5","author":"L Rached","year":"2024","unstructured":"Rached L, Peyre-Pradat F, Spotti M, Baldini C, Laparra A, Lambotte O, Sakkal M, Perret A, Viansone A, Michiels S, Delaloge S, Pistilli B, Ribeiro JM (2024) Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer. ESMO Real World Data Digit Oncol 5:100061. https:\/\/doi.org\/10.1016\/j.esmorw.2024.100061","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"8071_CR20","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1158\/1078-0432.Ccr-20-3646","volume":"27","author":"P Sharma","year":"2021","unstructured":"Sharma P, Kimler BF, O\u2019Dea A, Nye L, Wang YY, Yoder R, Staley JM, Prochaska L, Wagner J, Amin AL, Larson K, Balanoff C, Elia M, Crane G, Madhusudhana S, Hoffmann M, Sheehan M, Rodriguez R, Finke K, Shah R, Satelli D, Shrestha A, Beck L, McKittrick R, Pluenneke R, Raja V, Beeki V, Corum L, Heldstab J, LaFaver S, Prager M, Phadnis M, Mudaranthakam DP, Jensen RA, Godwin AK, Salgado R, Mehta K, Khan Q (2021) Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP). Clin Cancer Res 27:975\u2013982. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-3646","journal-title":"Clin Cancer Res"},{"key":"8071_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","volume":"10","author":"P Sharma","year":"2024","unstructured":"Sharma P, Stecklein SR, Yoder R, Staley JM, Schwensen K, O\u2019Dea A, Nye L, Satelli D, Crane G, Madan R, O\u2019Neil MF, Wagner J, Larson KE, Balanoff C, Kilgore L, Phadnis MA, Godwin AK, Salgado R, Khan QJ, O\u2019Shaughnessy J (2024) Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial. JAMA Oncol 10:227\u2013235. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5033","journal-title":"JAMA Oncol"},{"key":"8071_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1177\/17407745241304114","volume":"22","author":"ND Agaronnik","year":"2025","unstructured":"Agaronnik ND, Peters MLB, Iezzoni LI (2025) Exclusion of people from oncology clinical trials based on functional status. Clin Trials 22:367\u2013373. https:\/\/doi.org\/10.1177\/17407745241304114","journal-title":"Clin Trials"},{"key":"8071_CR23","unstructured":"Greater Plains Collaborative (2026) Greater Plains Collaborative Clinical Research Network. https:\/\/gpcnetwork.org\/. Accessed Feb 12"},{"key":"8071_CR24","doi-asserted-by":"publisher","first-page":"e2400196","DOI":"10.1200\/CCI-24-00196","volume":"8","author":"BD McDowell","year":"2024","unstructured":"McDowell BD, O\u2019Rorke MA, Schroeder MC, Chrischilles EA, Spinka CM, Waitman LR, Anuforo K, Araya A, Bah H, Barlocker J, Chandaka S, Cowell LG, Geary CR, Gupta S, Horne BD, Knosp BM, Lai AM, Mandhadi V, Mohammad Mosa AS, Reeder P, Ryu G, Shukwit B, Smith C, Stoddard AJ, Syed M, Syed S, Taylor BW, VanWormer JJ (2024) Implementing Cancer Registry Data With the PCORnet Common Data Model: The Greater Plains Collaborative Experience. JCO Clin Cancer Inf 8:e2400196. https:\/\/doi.org\/10.1200\/CCI-24-00196","journal-title":"JCO Clin Cancer Inf"},{"key":"8071_CR25","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/jamia\/ocab269","volume":"29","author":"LR Waitman","year":"2022","unstructured":"Waitman LR, Song X, Walpitage DL, Connolly DC, Patel LP, Liu M, Schroeder MC, VanWormer JJ, Mosa AS, Anye ET, Davis AM (2022) Enhancing PCORnet Clinical Research Network data completeness by integrating multistate insurance claims with electronic health records in a cloud environment aligned with CMS security and privacy requirements. J Am Med Inf Assoc 29:660\u2013670. https:\/\/doi.org\/10.1093\/jamia\/ocab269","journal-title":"J Am Med Inf Assoc"},{"key":"8071_CR26","unstructured":"North American Association of Central Cancer Registries (2026) Site Specific Data Items: Breast. https:\/\/apps.naaccr.org\/ssdi\/schema\/breast\/?breadcrumbs=(~schema_list~)"},{"key":"8071_CR27","unstructured":"National Cancer Institute Healthcare Delivery Research Program (2026) SEER-Medicare: Comorbidity SAS Macros. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/calculation.html. Accessed Feb 12"},{"key":"8071_CR28","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1158\/1055-9965.Epi-24-0833","volume":"34","author":"AM Noone","year":"2025","unstructured":"Noone AM, Mariotto AB, Hong YD, Enewold L (2025) Assessing 1-Year Comorbidity Prevalence and Its Survival Implications in Medicare Beneficiaries Diagnosed with Cancer: Insights from a New SEER-Medicare Resource. Cancer Epidemiol Biomarkers Prev 34:182\u2013189. https:\/\/doi.org\/10.1158\/1055-9965.Epi-24-0833","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"8071_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/s1470-2045(24)00757-5","volume":"26","author":"N Zdenkowski","year":"2025","unstructured":"Zdenkowski N, Kuper-Hommel MJJ, Niman SM, Francis PA, Baron-Hay S, Fox W, Menzies AM, Angus R, Punie K, Zardawi S, Regan MM, Loi S (2025) Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902\/IBCSG 61\u2009\u2013\u200920; Neo-N): a non-comparative, open-label, randomised, phase 2 trial. Lancet Oncol 26:367\u2013377. https:\/\/doi.org\/10.1016\/s1470-2045(24)00757-5","journal-title":"Lancet Oncol"},{"key":"8071_CR30","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1200\/jco.2016.68.4068","volume":"34","author":"EL Mayer","year":"2016","unstructured":"Mayer EL, Burstein HJ (2016) Chemotherapy for Triple-Negative Breast Cancer: Is More Better? J Clin Oncol 34:3369\u20133371. https:\/\/doi.org\/10.1200\/jco.2016.68.4068","journal-title":"J Clin Oncol"},{"key":"8071_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s1470-2045(25)00028-2","volume":"26","author":"A Gon\u00e7alves","year":"2025","unstructured":"Gon\u00e7alves A, de Nonneville A (2025) Tailoring chemoimmunotherapy de-escalation in early-stage triple-negative breast cancer. Lancet Oncol 26:273\u2013274. https:\/\/doi.org\/10.1016\/s1470-2045(25)00028-2","journal-title":"Lancet Oncol"},{"key":"8071_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jco-25-02336","volume":"44","author":"RK Yadav","year":"2026","unstructured":"Yadav RK, Miller KD (2026) Carboplatin for Premenopausal Triple-Negative Breast Cancer: Time to Rethink the Neoadjuvant Standard? J Clin Oncol 44:1\u20134. https:\/\/doi.org\/10.1200\/jco-25-02336","journal-title":"J Clin Oncol"},{"key":"8071_CR33","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1200\/JCO.24.00372","volume":"42","author":"M Kok","year":"2024","unstructured":"Kok M, Gielen RJ, Adams S, Lennerz JK, Sharma P, Loibl S, Reardon E, Sonke G, Linn S, Delaloge S, Lacombe D, Robinson T, Badve S, Martin M, Balko JM, Ignatiadis M, Curigliano G, Wolff AC, Mittendorf EA, Loi S, Pusztai L, Tolaney SM, Salgado R (2024) Academic Uphill Battle to Personalize Treatment for Patients With Stage II\/III Triple-Negative Breast Cancer. J Clin Oncol 42:3523\u20133529. https:\/\/doi.org\/10.1200\/JCO.24.00372","journal-title":"J Clin Oncol"},{"key":"8071_CR34","unstructured":"Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple (2026) Negative Breast Cancer. https:\/\/clinicaltrials.gov\/study\/NCT05929768. Accessed July 3"},{"key":"8071_CR35","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01100-2018","author":"CM Cramer-van der Welle","year":"2018","unstructured":"Cramer-van der Welle CM, Peters BJM, Schramel F, Klungel OH, Groen HJM, van de Garde EMW (2018) Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer. Eur Respir J 52. https:\/\/doi.org\/10.1183\/13993003.01100-2018","journal-title":"Eur Respir J 52"},{"key":"8071_CR36","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.athoracsur.2020.03.022","volume":"110","author":"LA Pluchino","year":"2020","unstructured":"Pluchino LA, D\u2019Amico TA (2020) National Comprehensive Cancer Network Guidelines: Who Makes Them? What Are They? Why Are They Important? Ann Thorac Surg 110:1789\u20131795. https:\/\/doi.org\/10.1016\/j.athoracsur.2020.03.022","journal-title":"Ann Thorac Surg"},{"key":"8071_CR37","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol.2020.2965","volume":"6","author":"KD Yu","year":"2020","unstructured":"Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, Zhuang ZG, Song CG, Lin XY, Toss A, Ricci F, Shen ZZ, Shao ZM (2020) Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol 6:1390\u20131396. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2965","journal-title":"JAMA Oncol"},{"key":"8071_CR38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1200\/jco-25-02412","volume":"44","author":"X Chen","year":"2026","unstructured":"Chen X, Huang J, Shi H, Zhu J, Wu W, Ye G, He Q, Shi Y, Zhang A, Xie X, Wang X, Chen X, Wu W, Wu J, Li Z, Li Z, Dai Y, Ren W, Shao Q, Chen Y, Zeng Y, Zhang F, Dong S, Pegram MD, Shen K (2026) Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial. J Clin Oncol 44:143\u2013152. https:\/\/doi.org\/10.1200\/jco-25-02412","journal-title":"J Clin Oncol"},{"key":"8071_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1200\/jco-25-01023","volume":"44","author":"S Gupta","year":"2026","unstructured":"Gupta S, Nair N, Hawaldar RW, Joshi S, Gulia S, Shet T, Sarin R, Parmar V, Desai S, Ghosh J, Wadasadawala T, Vanmali V, Panhale T, Parab P, Patil A, Chitkara G, Rath S, Bajpai J, Pathak R, Popat P, Thakur M, Badwe RA (2026) Addition of Carboplatin to Sequential Taxane-Anthracycline Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Phase III Randomized Controlled Trial. J Clin Oncol 44:9\u201319. https:\/\/doi.org\/10.1200\/jco-25-01023","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08071-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08071-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08071-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:54:27Z","timestamp":1790312067000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08071-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8071"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08071-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol for this observational study was reviewed by the Institutional Review Board at the University of Iowa and determined not to be human subjects research because of the deidentified data and minimal risk to patients.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial interests Matthew R. Kroll, Mary C. Schroeder, Joan M. Neuner, Brahmendra R. Viyyuri, Aditya Ravindra, Dana McDougall, Cole G. Chapman, Nicole M. G. Fleege, Elizabeth A. Chrischilles, and Xing Song declare they have no financial interests. Sneha Phadke has received research funding from Pfizer, Boehringer Ingelheim, AstraZeneca, Olema, Merck, genentech\/Hoffman\/LaRoche, Novartis; honorarium from OncLive; and support from BinayTara Foundation; consultant for Nayva Network.Non-financial interests Matthew R. Kroll, Mary C. Schroeder, Joan M. Neuner, Brahmendra R. Viyyuri, Aditya Ravindra, Dana McDougall, Cole G. Chapman, Nicole M. G. Fleege, Elizabeth A. Chrischilles, and Xing Song declare they have no non-financial interests. Sneha Phadke has served as an unpaid consultant for Starling Biosciences.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"7"}}